• Citron OGD2, Iron, and Citrus Canker Resistance

  2026-10-10

  The reference study by Hao et al. identifies CmOGD2 as an iron-uptake-linked regulator of citron resistance to citrus canker and connects its activity with reactive oxygen species accumulation and probable ferroptosis. Its main innovation is a multilayer regulatory model involving CmENO2, CmZAT10.1, and the Xanthomonas citri effector pthA4, while also highlighting important limits in interpreting ROS and ferroptosis-related evidence.

• LGK-974 and PORCN Inhibition: Research Context

  2026-10-09

  LGK-974 is a research-stage PORCN inhibitor used to investigate ligand-dependent Wnt signaling. Evidence supplied here includes vendor-described oncology activity and a 2025 peer-reviewed mouse study suggesting that PORCN inhibition can reduce abnormal bone formation in Sost-deficient models, while important questions about human translation, long-term safety, pathway selectivity, and disease-specific benefit remain unresolved.

• Genotyping Kit for Target Alleles: Evidence and Scope

  2026-10-09

  A source-grounded overview of the Genotyping Kit for target alleles, its supplier-described role in PCR-based genotyping, and its potential conceptual relevance to molecular biology research. The article separates product claims from peer-reviewed findings, using a 2024 PLOS Pathogens study on Lactobacillus gasseri and experimental colitis to clarify what genotyping can—and cannot—establish about biological mechanism, phenotype, and translational relevance.

• Substance P: Signaling, Applications, and Evidence

  2026-10-08

  A source-grounded overview of Substance P as a tachykinin neuropeptide, covering NK1-receptor signaling, pain transmission research, inflammation, immune response modulation, conceptual study applications, evidence strength, and important limitations. It also explains why a supplied fluorescence-classification study should not be interpreted as direct evidence about Substance P biology or measurement.

• Deep Learning for iPSC-CM Cardiotoxicity Screening

  2026-10-08

  Grafton et al. present a high-content screening framework that combines induced pluripotent stem cell-derived cardiomyocytes with deep-learning image analysis to identify cellular patterns associated with cardiotoxicity. The study supports target-agnostic phenotypic screening as an early drug-discovery tool, while also showing why a computational phenotype score should be interpreted as a liability signal rather than a complete mechanistic or clinical assessment.

• Aedes aegypti Xenobiotic Clearance and OCT Expression

  2026-10-07

  Kennel and Rouhier examined how three xenobiotics, including Olsalazine Sodium, affected excretion, mortality, and expression of six putative organic cation transporters in female Aedes aegypti. The study’s main contribution is to connect organism-level clearance phenotypes with exploratory transporter-expression data while showing that compound structure may influence excretion more strongly than measured transcriptional responses.

• Gramine, Ferroptosis, and the CUL3–MTDH Axis

  2026-10-07

  A 2026 study reports that Gramine, also known as 1-(1H-indol-3-yl)-N,N-dimethylmethanamine, suppresses triple-negative breast cancer models through a CUL3–MTDH mechanism linked to ferroptosis. The findings connect compound–target engagement with changes in redox markers, mitochondrial morphology, and tumor growth, while remaining preclinical and model-dependent.

• Octenidine Dihydrochloride: Evidence Overview

  2026-10-06

  A source-grounded overview of octenidine dihydrochloride covering its antiseptic research context, membrane-disruption rationale, findings from a 2024 study of related gemini quaternary ammonium compounds, conceptual applications, and key evidence limitations.

• GSK 2837808A: Testing the Lactate–Immunity Link

  2026-10-06

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor that can help distinguish LDHA-dependent lactate production from the broader NAT1–ENO1–lactate signaling network. This article interprets its value for cancer metabolism research while separating validated hepatocellular carcinoma evidence from hypothesis-generating colorectal cancer applications.

• GSK 2837808A in LDHA and CRC Metabolism Research

  2026-10-05

  GSK 2837808A is a supplier-described LDHA-focused small molecule relevant to cancer metabolism research, while recent colorectal cancer evidence centers on the NAT1–ENO1–lactate–PD-L1 pathway. This overview compares the compound’s reported biochemical and pharmacokinetic profile with findings from a 2026 MedComm study, emphasizing that LDHA inhibition has not yet been directly validated as a way to reproduce the study’s immune effects. The evidence remains preclinical, model-dependent, and insufficient to support clinical or therapeutic conclusions.

• DiI (DiIC18(3)) Product Overview

  2026-10-05

  DiI (DiIC18(3)), SKU B8804, is an APExBIO-listed lipophilic orange fluorescent membrane probe. The available information supports product identity and conceptual scope only; no matched paper evidence was supplied to establish performance, mechanism, or application-specific outcomes.

• Anlotinib and Angiogenesis: Evidence from a 2018 Study

  2026-10-04

  The 2018 Gene study identified anlotinib as a multi-target tyrosine kinase inhibitor that suppresses angiogenic signaling through VEGFR2, PDGFRβ, FGFR1, and downstream ERK. By combining endothelial-cell, ex vivo tissue, and CAM models, the work linked receptor-level inhibition with reduced migration, tube formation, and vascular sprouting, while leaving clinical translation to future research.

• From Antibody Maps to Translational Readouts

  2026-10-03

  Orthopoxvirus antibody discovery increasingly depends on connecting epitope-level mechanism with reproducible human IgG measurement. This thought-leadership article examines how the Cy3 Goat Anti-Human IgG (H+L) Antibody can support research readouts while distinguishing product attributes from evidence generated in preclinical antibody studies.

• Pheromone Signaling and Neurodegeneration in C. elegans

  2026-10-02

  Peng et al. show that pheromone exposure during the L1 stage can reprogram neuronal development and accelerate neurodegeneration in adult C. elegans. The study identifies a synergistic ASK–ASI–AIA circuit that connects environmental chemical sensing with insulin-like signaling and reduced neuronal autophagy.

• Exemestane Workflows for Aromatase Research

  2026-10-01

  Build reproducible aromatase assays with Exemestane, from solvent preparation and time-dependent inhibition studies to breast cancer research models. Practical controls, concentration guidance, and troubleshooting help distinguish true estrogen biosynthesis inhibition from matrix, precipitation, or readout artifacts.

8658 records 1/578 page Next 12345 下5页 Last page